Corpus overview


Overview

MeSH Disease

Transmission

Seroprevalence
    displaying 1 - 10 records in total 68
    records per page




    The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection MESHD by associating with L-SIGN and DC-SIGN

    Authors: Wai Tuck Soh; Yafei Liu; Emi E Nakayama; Chikako Ono; Shiho Torii; Hironori Nakagami; Yoshiharu Matsuura; Tatsuo Shioda; Hisashi Arase; Reid Simon; Ivan Grishagin; Laura Brovold; Ewy A Mathé; Matthew D Hall; Samuel G Michael; Alexander G Godfrey; Jordi Mestres; Lars J Jensen; Tudor I Oprea; Isabel Crooker; Sara Y Del Valle; Guido Espana; Geoffrey Fairchild; Richard C Gerkin; Timothy C Germann; Quanquan Gu; Xiangyang Guan; Lihong Guo; Gregory R Hart; Thomas J Hladish; Nathaniel Hupert; Daniel Janies; Cliff C Kerr; Daniel J Klein; Eili Klein; Gary Lin; Carrie Manore; Lauren Ancel Meyers; John Mittler; Kunpeng Mu; Rafael C NUNez; Rachel Oidtman; Remy Pasco; Ana Pastore y Piontti Pastore y Piontti; Rajib Paul; Carl AB Pearson; Dianela Perdomo; T Alex Perkins; Kelly Pierce; Alexander N Pillai; Rosalyn Cherie Rael; Katherine Rosenfeld; Chrysm Watson Ross; Julie A Spencer; Arlin B Stoltzfus; Kok Ben Toh; Shashaank Vattikuti; Alessandro Vespignani; Lingxiao Wang; Lisa White; Pan Xu; Yupeng Yang; Osman N Yogurtcu; Weitong Zhang; Yanting Zhao; Difan Zou; Matthew Ferrari; David Pannell; Michael Tildesley; Jack Seifarth; Elyse Johnson; Matthew Biggerstaff; Michael Johansson; Rachel B Slayton; John Levander; Jeff Stazer; Jessica Salermo; Michael C Runge

    doi:10.1101/2020.11.05.369264 Date: 2020-11-05 Source: bioRxiv

    The widespread occurrence of SARS-CoV-2 has had a profound effect on society and a vaccine is currently being developed. Angiotensin-converting enzyme 2 (ACE2) is the primary host cell receptor that interacts with the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Although pneumonia MESHD pneumonia HP is the main symptom in severe cases of SARS-CoV-2 infection MESHD, the expression levels of ACE2 in the lung is low, suggesting the presence of another receptor for the spike protein. In order to identify the additional receptors for the spike protein, we screened a receptor for the SARS-CoV-2 spike protein from the lung cDNA library. We cloned L-SIGN as a specific receptor for the N-terminal domain (NTD) of the SARS-CoV-2 spike protein. The RBD of the spike protein did not bind to L-SIGN. In addition, not only L-SIGN but also DC-SIGN, a closely related C-type lectin receptor to L-SIGN, bound to the NTD of the SARS-CoV-2 spike protein. Importantly, cells expressing L-SIGN and DC-SIGN were both infected by SARS-CoV-2. Furthermore, L-SIGN and DC-SIGN induced membrane fusion by associating with the SARS-CoV-2 spike protein. Serum SERO antibodies SERO from infected patients and a patient-derived monoclonal antibody SERO against NTD inhibited SARS-CoV-2 infection of L-SIGN MESHD or DC-SIGN expressing cells. Our results highlight the important role of NTD in SARS-CoV-2 dissemination through L-SIGN and DC-SIGN and the significance of having anti-NTD neutralizing antibodies SERO in antibody SERO-based therapeutics.

    Tocilizumab in nonventilated patients hospitalized with Covid-19 MESHD pneumonia HP pneumonia MESHD

    Authors: Carlos Salama; Jian Han; Linda Yau; William G. Reiss; Benjamin Kramer; Jeffrey D. Neidhart; Gerard J. Criner; Emma Kaplan-Lewis; Rachel Baden; Lavannya Pandit; Miriam L. Cameron; Julia Garcia-Diaz; Victoria Chávez; Martha Mekebeb-Reuter; Ferdinando Lima Menezes; Reena Shah; Maria F. González-Lara; Beverly Assman; Jamie Freedman; Shalini V. Mohan; Felix Frueh; Brett L Hurst; Hong Wang; Klaudia I Kocurek; Frank M Raushel; Jair L. Siqueira-Neto; Thomas D Meek; James H McKerrow

    doi:10.1101/2020.10.21.20210203 Date: 2020-10-23 Source: medRxiv

    Background: Coronavirus disease 2019 MESHD ( Covid-19 MESHD) pneumonia HP pneumonia MESHD is often associated with hyperinflammation. Safety and efficacy of the anti-interleukin-6 receptor antibody SERO tocilizumab was evaluated in patients hospitalized with Covid-19 MESHD pneumonia HP pneumonia MESHD. Methods: Nonventilated patients hospitalized with Covid-19 MESHD pneumonia MESHD pneumonia HP were randomized (2:1) to tocilizumab (8 mg/kg intravenous) or placebo plus standard care. Sites enrolling high-risk and minority populations were emphasized. The primary endpoint was cumulative proportion of patients requiring mechanical ventilation or who had died by Day 28. Results: Of 389 randomized patients, 249 patients received tocilizumab and 128 received placebo in the modified intent-to-treat population (Hispanic/Latino, 56.0%; Black/African American, 14.9%; American Indian/Alaska Native, 12.7%; White, 12.7%; other/unknown, 3.7%). The cumulative proportion (95% confidence interval [CI]) of patients requiring mechanical ventilation or who had died by Day 28 was 12.0% (8.52% to 16.86%) and 19.3 % (13.34% to 27.36%) for the tocilizumab and placebo arms, respectively (log-rank P=0.0360; hazard ratio, 0.56 [95% CI, 0.33 to 0.97]). Median time to clinical failure up to Day 28 favored tocilizumab over placebo (hazard ratio 0.55 [95% CI, 0.33 to 0.93]). All-cause mortality by Day 28 was 10.4% with tocilizumab and 8.6% with placebo (weighted difference, 2.0% [95% CI, -5.2% to 7.8%). In the safety population, serious adverse events occurred in 15.2% of tocilizumab patients (38/250 patients) and 19.7% of placebo patients (25/127). Conclusions: This trial demonstrated the efficacy and safety of tocilizumab over placebo in reducing the likelihood of progression to requiring mechanical ventilation or death MESHD in nonventilated patients hospitalized with Covid-19 MESHD pneumonia MESHD pneumonia HP.

    Tocilizumab is associated with reduction in inflammation MESHD and improvement in P/F ratio in critically sick COVID19 MESHD patients

    Authors: Muhammad Asim Rana; Mubashar Sultan Hashmi; Muhammad Muneeb Ullah Saif; Muhammad Faisal Munir; Ahad Qayyum; Rizwan Pervaiz; Muhammad Mansoor Hafeez; Graham Cooke; Timothy B Hallett; Katharina D Hauck; Peter J White; Mark R Thursz; Shevanthi Nayagam; Brendan Flannery; Ricardo Gilead Baibich; Iris Bigler; Matan Malul; Rotem Rishti; Asher Brenner; Yair E. Lewis; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.20.20210195 Date: 2020-10-21 Source: medRxiv

    Introduction: Coronavirus disease 2019 MESHD was initially detected in China and has been declared a global pandemic by World Health Organization on March 11, 2020. In the majority of patients, SARS-CoV-2 causes a mild to moderate illness characterized by fever MESHD fever HP and respiratory symptoms MESHD, with or without evidence of pneumonia HP pneumonia MESHD. The recent studies suggest that anti-cytokine targeted therapies might be associated with benefit for patients with severe COVID-19 MESHD especially in improving respiratory failure HP respiratory failure MESHD. Tocilizumab, a monoclonal antibody SERO against interleukin 6 (IL6) receptor, is associated with clinical benefit for COVID-19 MESHD patients as it inhibits IL6 and decreases inflammation MESHD. Methods: As Tocilizumab has been an important part of our treatment and a strict criterion was followed to administer Tocilizumab, a retrospective study design used to assess the beneficial effects of Tocilizumab in improvement of ratio partial pressure of arterial Oxygen and fraction of inspired Oxygen (PaO2/FiO2 or P/F ratio) and C- reactive protein (CRP) in COVID19 MESHD patients has been done. 60 patients were taken for this study by using convenient sampling technique the data of demographics, laboratory results, and clinical outcomes i.e. improvement of respiratory failure MESHD respiratory failure HP depicted in the form of PF Ratio were obtained from the medical records, Statistical analysis was done with SPSS, version 21.0. Results: Sixty patients (47 males TRANS and 13 females TRANS) with COVID-19 MESHD were included in this study, the mean age TRANS of patients was 53.83 (14-81) years. After administration of Tocilizumab the lab parameters were changed as CRP decreased down to .40 (9.6-73) mg/L but other parameters were not affected. The PF ratio improved in COVID-19 MESHD patients after administration of Tocilizumab the median of PF Ratio before treatment was 108 (52-362) and improved up to 128 (37-406) after Tocilizumab therapy. Conclusion: In summary, Tocilizumab appears to be associated with improvement in P/F Ratio and CRP in COVID19 MESHD patients but other markers did not improve in response to Tocilizumab therapy in severely ill COVID-19 MESHD patients.

    EFFECT OF CONVALESCENT PLASMA SERO ON MORTALITY IN PATIENTS WITH COVID-19 MESHD PNEUMONIA HP

    Authors: Martin R Salazar; Soledad E Gonzalez; Lorena Regairaz; Noelia S Ferrando; Veronica Gonzalez; Patricia M Carrera; Laura Muñoz; Santiago A Pesci; Juan M Vidal; Nicolas Kreplak; Elisa Estenssoro; Harendra Guturu; Ahna R. Girshick; Kristin A. Rand; Eurie L. Hong; Catherine A. Ball; Stefan VANEL; Pierre MENDIHARAT; Klaudia PORTEN; William HENNEQUIN; Clair MILLS; Francisco LUQUERO

    doi:10.1101/2020.10.08.20202606 Date: 2020-10-09 Source: medRxiv

    Abstract Background Convalescent plasma SERO, widely utilized in viral infections that induce neutralizing antibodies SERO, has been proposed for COVID-19 MESHD, and preliminary evidence shows that it might have beneficial effect. Our objective was to compare epidemiological characteristics and outcomes between patients who received convalescent plasma SERO for COVID-19 MESHD and those who did not, admitted to hospitals in Buenos Aires Province, Argentina, throughout the pandemic. Methods This is a multicenter, retrospective cohort study of 2-month duration beginning on June 1, 2020, including unselected, consecutive adult TRANS patients with diagnosed COVID-19 MESHD, admitted to 215 hospitals with pneumonia HP pneumonia MESHD. Epidemiological and clinical variables were registered in the Provincial Hospital Bed Management System. Convalescent plasma SERO was supplied as part of a centralized, expanded access program. Results We analyzed 3,529 patients with pneumonia MESHD pneumonia HP, predominantly male TRANS, aged TRANS 62{+/-}17, with arterial hypertension HP hypertension MESHD and diabetes MESHD as main comorbidities; 51.4% were admitted to the ward, 27.1% to the Intensive Care Unit (ICU), and 21.7% to the ICU with mechanical ventilation requirement (ICU-MV). 28-day mortality was 34.9%; and was 26.3%, 30.1% and 61.4% for ward, ICU and ICU-MV MESHD patients. Convalescent plasma SERO was administered to 868 patients (24.6%); their 28-day mortality was significantly lower (25.5% vs. 38.0%, p<0.001). No major adverse effects occurred. Logistic regression analysis identified age TRANS, ICU admission with and without MV requirement, diabetes MESHD and preexistent cardiovascular disease MESHD as independent predictors of 28-day mortality, whereas convalescent plasma SERO administration acted as a protective factor. Conclusions Our study suggests that the administration of convalescent plasma SERO in COVID-19 MESHD pneumonia HP pneumonia MESHD admitted to the hospital might be associated with decreased mortality.

    The Importance of SARS-CoV-2 N-Ag Serodiagnostics for the Management of COVID-19 MESHD Pneumonia HP in Hospital Settings

    Authors: Yuri S. Lebedin; Olga V. Lyang; Anaida G. Galstyan; Anna V. Panteleeva; Vsevolod V. Belousov; Denis Rebrikov

    doi:10.21203/rs.3.rs-88799/v1 Date: 2020-10-06 Source: ResearchSquare

    We report evaluation of the SARS-CoV-2 nucleocapsid antigen (N-Ag) and respective antibodies SERO as diagnostic markers in pneumonia HP pneumonia MESHD patients. The study was conducted at the height of COVID-19 MESHD pandemic in Moscow, Russia. It included 425 emergency patients with clinical signs of COVID-19 MESHD pneumonia MESHD pneumonia HP, of which 280 (66%) were positive for either serum SERO N-Ag and/or its respective antibodies SERO. We demonstrate the total prevalence SERO of N-Ag seroconversion in SARS-CoV-2-associated pneumonia HP pneumonia MESHD patients within 3-5 days after hospital admission. The results indicate high feasibility of SARS-CoV-2 serodiagnostics in emergency patients.

    Tocilizumab improves survival in severe COVID-19 MESHD pneumonia HP pneumonia MESHD with persistent hypoxia MESHD: A retrospective cohort study with follow-up from Mumbai, India

    Authors: YOJANA Gokhale; Rakshita Mehta; Uday Kulkarni; Nitin Karnik; Sushant Gokhale B.Tech; Uma Sundar; Swati Chavan; Akshay Kor; Sonal Thakur; Trupti Trivedi; Naveen Kumar; Sujata Bavej; Aniket Wadal; Shaonak Kolte; Aukshan Deolankar; Sangeeta Pednekar; Lalana Kalekar; Rupal Padiyar; Charulata Londhe; Pramod Darole; Sujata Pol; Seema Bansode Goke; Namita Padwal; Dharmendra Pandye; Dhirendra Yadav; Anagha Joshi; Harshad Badgujar; Mayuri Trivedi; Priyanshu Shah; Prerana Bhavsar

    doi:10.21203/rs.3.rs-88185/v1 Date: 2020-10-05 Source: ResearchSquare

    Background: Cytokine storm triggered by Severe Corona Virus Disease MESHD 2019 ( COVID-19 MESHD) is associated with high mortality. With high ‘Interlukin -6’ (IL-6) levels reported in COVID-19 MESHD deaths in China1, IL-6 is considered to be the key player in COVID-19 MESHD cytokine storm. Tocilizumab, a monoclonal antibody SERO against IL-6 receptor, is used on compassionate grounds for treatment of COVID-19 MESHD cytokine storm. Aim of this study was to assess effect of tocilizumab on mortality due to COVID-19 MESHD cytokine storm.Method: This retrospective, observational study included patients of severe COVID-19 MESHD pneumonia HP pneumonia MESHD with persistent hypoxia MESHD (defined as saturation 94% or less on supplemental Oxygen of 15 L per minute through non-rebreathing mask or PaO2/FiO2 ratio of less than 200) who were admitted to tertiary care center in Mumbai, India, between 31st March to 5th July 2020. In addition to standard care, single Inj. Tocilizumab 400mg was given intravenously to 151 consecutive COVID-19 MESHD patients with persistent hypoxia MESHD from 13th May to 5th July 2020. These 151 patients were retrospectively analysed and compared with historic controls i.e consecutive COVID-19 MESHD patients with persistent hypoxia MESHD, defined as above (N=118, from our first COVID-19 MESHD admission on 31st March to 12th May 2020 ie till tocilizumab was available in hospital). Univariate and multivariate Cox regression analysis was performed for identifying predictors of survival. Statistical analysis was performed using IBM SPSS version 26.Results: On multivariate Cox regression analysis, independent predictors of survival were use of tocilizumab (HR 0.621, 95% CI 0.427-0.903, P 0.013) and higher oxygen saturation.Conclusion: Tocilizumab improved survival in severe COVID-19 MESHD pneumonia HP pneumonia MESHD with persistent hypoxia MESHD

    Tocilizumab improves survival in severe COVID-19 MESHD pneumonia HP pneumonia MESHD with persistent hypoxia MESHD: A retrospective cohort study with follow-up from Mumbai, India

    Authors: YOJANA gokhale; Rakshita Mehta; Uday Kulkarni; Nitin Karnik; Sushant Gokhale; Uma Sundar; Swati Chavan; Akshay Kor; Sonal Thakur; Tripti Triwedi; Naveen Kumar; Sujata Baveja; Aniket Wadal; Shaonak Kolte; Aukshan Deolankar; Sangeeta Pednekar; Lalana Kalekar; Rupal Padiyar; Charulata Londhe; Pramod Darole; Sujata Pol; Seema Bansode Gokhe; Namita Padwal; Dharmendra Pandey; Dhirendra Yadav; Anagha Joshi; Harshal Badgujar; Mayuri Trivedi; Priyanshu Shah; Prerna Bhavsar

    doi:10.21203/rs.3.rs-80152/v1 Date: 2020-09-18 Source: ResearchSquare

    BackgroundCytokine storm triggered by Severe Corona Virus Disease MESHD 2019 ( COVID-19 MESHD) is associated with high mortality. With high ‘Interlukin -6’ (IL-6) levels reported in COVID-19 MESHD related deaths in China1, IL-6 is considered to be the key player in COVID-19 MESHD cytokine storm. Tocilizumab, a monoclonal antibody SERO against IL-6 receptor, is used on compassionate grounds for treatment of COVID-19 MESHD cytokine storm. The aim of this study was to assess effect of tocilizumab on mortality due to COVID-19 MESHD cytokine storm.MethodThis retrospective, observational study included patients of severe COVID-19 MESHD pneumonia HP pneumonia MESHD with persistent hypoxia MESHD (defined as saturation 94% or less on supplemental Oxygen of 15 L per minute through non-rebreathing mask or PaO2/FiO2 ratio of less than 200) who were admitted to a tertiary care center in Mumbai, India, between 31st March to 5th July 2020. In addition to standard care, single Inj. Tocilizumab 400mg was given intravenously to 151 consecutive COVID-19 MESHD patients with persistent hypoxia MESHD, from 13th May to 5th July 2020. These 151 patients were retrospectively analysed and compared with historic controls, i.e consecutive COVID-19 MESHD patients with persistent hypoxia MESHD, defined as stated above (N=118, from our first COVID-19 MESHD admission on 31st March to 12th May 2020 i.e, till tocilizumab was available in hospital). Univariate and multivariate Cox regression analysis was performed for identifying predictors of survival. Statistical analysis was performed using IBM SPSS version 26.ResultsOn multivariate Cox regression analysis, independent predictors of survival were use of tocilizumab (HR 0.621, 95% CI 0.427-0.903, P 0.013) and higher oxygen saturation.Interpretation: Tocilizumab improved survival in severe COVID-19 MESHD pneumonia HP pneumonia MESHD with persistent hypoxia MESHD

    New onset of Myasthenia Gravis MESHD in a patient with COVID-19 MESHD: A novel case report and literature review

    Authors: Shitiz Sriwastava; Medha Tandon; Saurabh Kataria; Maha Daimee; Shumaila Sultan

    doi:10.21203/rs.3.rs-77694/v1 Date: 2020-09-14 Source: ResearchSquare

    The novel coronavirus outbreak of SARS-CoV-2 first began in Wuhan, China in December, 2019. The most striking manifestation is atypical pneumonia MESHD pneumonia HP and respiratory complications MESHD, however various neurological manifestations are now well recognized. Currently, there have been a very few case reports in regards to COVID-19 MESHD in patients with known history of myasthenia gravis MESHD. Myasthenia gravis MESHD ( MG MESHD) causes muscle weakness HP muscle weakness MESHD, especially respiratory muscles in high-risk COVID-19 MESHD patients that can lead to severe respiratory compromise. There are few reported cases of severe myasthenia crisis MESHD following COVID-19 MESHD, likely due to the involvement of the respiratory apparatus and from use of immunosuppressive medication. We report a first case MG MESHD developing secondary to COVID-19 MESHD infection in a 65-year-old woman. Two weeks prior to hospitalization, the patient suffered from cough HP, fever HP fever MESHD, diarrhea HP diarrhea MESHD and was found to be positive for COVID-19 MESHD via nasopharyngeal RT-PCR swab test. The electrodiagnostic test showed decremental response over more than 10% on repetitive nerve stimulation test of orbicularis oculi. She tested positive for antibodies SERO against Acetylcholine receptor (AchR). COVID-19 MESHD is known to cause release of inflammatory cytokines leading to immune-mediated damage. MG MESHD is an immune-mediated disorder caused due to molecular mimicry and autoantibodies against the neuromuscular junction. 

    Anakinra and Intravenous IgG versus Tocilizumab in the Treatment of COVID-19 MESHD Pneumonia HP

    Authors: Massa Zantah; Eduardo Dominguez Castillo; Andrew J. Gangemi; Maulin Patel; Junad Chowdhury; Steven Verga; Osheen Abramian; Mattew Zheng; Kevin Lu; Arthur Lau; Justin Levinson; Hauquing Zhao; Gerard J. Criner; Roberto Caricchio; Yousif Yousif; Fouad AboGazalah; Fuad Awwad; Khaled AlabdulKareem; Fahad AlGhofaili; Ahmed AlJedai; Hani Jokhdar; Fahad Alrabiah

    doi:10.1101/2020.09.11.20192401 Date: 2020-09-13 Source: medRxiv

    Background: COVID-19 MESHD can lead to acute respiratory failure HP respiratory failure MESHD and an exaggerated inflammatory response. Studies have suggested promising outcomes using monoclonal antibodies SERO targeting IL-1{beta} (Anakinra) or IL6 (Tocilizumab), however no head to head comparison was done between the two treatments. Herein, we report our experience in treating COVID-19 MESHD pneumonia MESHD pneumonia HP associated with cytokine storm with either subcutaneous Anakinra given concomitantly with intravenous immunoglobulin (IVIG), or intravenous Tocilizumab. Methods: Comprehensive clinical and laboratory data from patients with COVID-19 MESHD pneumonia MESHD pneumonia HP admitted at our hospital between March and May 2020 were collected. Patients who received either Anakinra/ IVIG or Tocilizumab were selected. Baseline characteristics including oxygen therapy, respiratory status evaluation using ROX index, clinical assessment using NEWS score and laboratory data were collected. Outcomes included mortality, intubation, ICU admission and length of stay. In addition, we compared the change in ROX index, NEWS score and inflammatory markers at days 7 and 14 post initiation of therapy. Results: 84 consecutive patients who received either treatment (51 in the Anakinra/ IVIG group and 33 in the Tocilizumab group) were retrospectively studied. Baseline inflammatory markers were similar in both groups. There was no significant difference regarding to death (21.6% vs 15.2%, p 0.464), intubation (15.7% vs 24.2%, p 0.329), ICU need (57.1% vs 48.5%, p 0.475) or length of stay (13+9.6 vs 14.9+11.6, p 0.512) in the Anakinra/IVIG and Tocilizumab, respectively. Additionally, the rate of improvement in ROX index, NEWS score and inflammatory markers was similar in both groups at days 7 and 14. Furthermore, there was no difference in the incidence of superinfection in both groups. Conclusion: Treating COVID-19 MESHD pneumonia HP pneumonia MESHD associated with cytokine storm features with either subcutaneous Anakinra/IVIG or intravenous Tocilizumab is associated with improved clinical outcomes in most subjects. The choice of treatment does not appear to affect morbidity or mortality. Randomized controlled trials are needed to confirm our study findings. Funding: None.

    Stepwise anti-inflammatory and anti-SARS-CoV-2 effects following convalescent plasma SERO therapy with full clinical recovery

    Authors: Aurelia Zimmerli; Matteo Monti; Craig Fenwick; Isabella Eckerle; Catherine Beigelman-Aubry; Celine Pellaton; Katia Jaton; Dominique Dumas; Gian-Marco Stamm; Laura Infanti; Heidrun Andreu-Ullrich; Daphne Germann; Marie Mean; Peter Vollenweider; Raphael Stadelmann; Maura Prella; Denis Comte; Benoit Guery; David Gachoud; Nathalie Rufer

    doi:10.21203/rs.3.rs-76799/v1 Date: 2020-09-12 Source: ResearchSquare

    Convalescent plasma SERO to treat coronavirus disease 2019 MESHD ( COVID-19 MESHD) is currently the focus of numerous clinical trials worldwide, but the criteria of treatment efficacy remain largely unknown. Here, we describe a severely immunosuppressed patient following rituximab and chemotherapy for chronic lymphoid leukemia HP lymphoid leukemia MESHD, who became infected by SARS-CoV-2. His prolonged viral disease was successfully cured after four cycles of convalescent plasma SERO. Its immunomodulatory properties led to the rapid improvement of inflammation MESHD, pneumonia HP pneumonia MESHD and blood SERO cell counts, already after the first cycle. Importantly, the cumulative increase in anti- SARS-CoV-2 neutralizing antibodies SERO following each plasma SERO transfusion was associated to progressive viral clearance, resulting in clinical recovery from infection. Our data provide insight into the different modes of action of plasma SERO components. Understanding the underlying mechanisms will help to optimize the treatment of COVID-19 MESHD patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.